LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EFIB 2021 launch event: biotech community discussed innovation solutions for a sustainable future

01/06/2021
NEWS RELEASE
Brussels, 27 May 2021

Last week EuropaBio organised EFIB 2021 kick-off webinar ‘How to accelerate biotech innovation for a sustainable future”. The event was co-hosted by DSM and Planet B.io, both located at the Biotech Campus Delft.

Agnes Borg, Industrial Biotechnology Director at EuropaBio, welcomed participants to the webinar, noting that industrial biotechnology is well placed to contribute to the objectives of the EU Green Deal.

Dr Claire Skentelbery, Director-General of EuropaBio, looks forward to welcoming participants to EFIB 2021 in Vienna, Austria with local host LISAvienna. Austria has a strong industrial biotechnology landscape so is the ideal backdrop for a return to an in-person conference. A key theme of EFIB2021 is how industrial biotechnology delivers across a range of sectors through innovative products & processes, while contributing towards EU Green Deal objectives. In particular, innovation will be showcased through the Start-up Village and Innovation Campus, for which applications are open until 16 June.

Cindy Gerhardt, Managing Director, Planet-B.io at the Biotech Campus Delft

Cindy introduced Planet-B.io as the open innovation ecosystem for industrial biotechnology. She discussed the benefits of collaboration between corporates and start-ups, from providing investment opportunities and increasing entrepreneurship for corporates to access capital, increased structure and credibility for start-ups. She shared Planet-B.io learnings on corporate-startup interactions in the DSM ecosystem, noting that financial, technical, and business support is crucial for start-ups. Joining a triple-helix, multi-tenant campus like the Biotech Campus Delft and becoming part of an innovation ecosystem can be a key step in accessing this support. Cindy also shared her positive experiences with the recent DSM meat replacement innovation challenge and discussed the valuable role that those competitions can provide to all parties. However, she advised that start-ups should thoroughly decide whether or not to take part in those challenges and that it would generally offer the best fit for founders if the requested scope is rather targeted to a specific topic, than only a broad call for innovation.

Amadeus Driando Ahnan-Winarno – Co-Founder & Head of Technology, Better Nature

Amadeus briefly introduced Better Nature, who won the EFIB2020 Start-Up Forum. Better Nature is a UK-based start-up that offers meat alternative food products using tempeh fermentation. With this approach, the company provides a plant-based alternative to other meat-free products which use artificial or ultra-processed ingredients. In the near future, the pipeline will also include the Better Nature burger and dairy ingredients. The focus of his talk was on what startups need in moving from lab to market, summarizing that confidentiality, customizability, scaleability, and product-market fit are among the major points to be addressed by founders, and that every product development stage has different needs. From his experience, up-scaling manufacturing processes is among one of the most challenging steps. Amadeus also provided insights on the most recent and successful crowdfunding campaign of his company.

Rob van der Meij (Partner, Capricorn Partners)

Rob’s opinion is that industrial biotech is the next stage of investment. In his presentation, he gave an overview of Capricorn Partner’s portfolio of which a majority is related to industrial biotechnology. With regard to the market Rob perceives industrial biotechnology as a sustainable alternatives to existing approaches in chemistry and other industrial sectors. Cost reductions in working with DNA and new platform technologies have contributed to more applications, he said. Rob added that biotech innovation in this field is not going for the lowest prices and also pointed to the fact that cars in their early days were not cheaper than horses. From his perspective, the drivers for industrial biotechnology are much stronger today than ten years ago. He particularly mentioned aspects related to consumer demand and policy and regulation such as the EU Green Deal. In addition, he emphasized that founders should not be shy with regard to defending their developments towards corporates and investors.

EFIB 2021 will take place 6-7 October 2021 in Vienna, Austria as an onsite event. More information, the programme and registration here.

EFIB 2021 launch event: biotech community discussed innovation solutions for a sustainable future


Download
Share
Alexandra Simionca
Alexandra Simionca

Related posts

03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more
25/06/2025

Hawkwood Biotech joins EuropaBio: Supporting Industrial Biotech with their Critical Challenges


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.